174 related articles for article (PubMed ID: 34935084)
1. Impact of house dust mite-driven asthma on children's school performance and activity.
Gómez C; Barrena J; García-Paz V; Plaza AM; Crespo P; Bejarano JA; Rodríguez AB; Ferré L; Farrarons L; Viñas M; Torán-Barona C; Pereiro A; Justicia JL; Nevot S
Eur J Pediatr; 2022 Apr; 181(4):1567-1574. PubMed ID: 34935084
[TBL] [Abstract][Full Text] [Related]
2. Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma.
Jutel M; Brüggenjürgen B; Richter H; Vogelberg C
Allergy; 2020 Aug; 75(8):2050-2058. PubMed ID: 32080856
[TBL] [Abstract][Full Text] [Related]
3. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
Agache I; Lau S; Akdis CA; Smolinska S; Bonini M; Cavkaytar O; Flood B; Gajdanowicz P; Izuhara K; Kalayci O; Mosges R; Palomares O; Papadopoulos NG; Sokolowska M; Angier E; Fernandez-Rivas M; Pajno G; Pfaar O; Roberts GC; Ryan D; Sturm GJ; van Ree R; Varga EM; van Wijk RG; Yepes-Nuñez JJ; Jutel M
Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767
[TBL] [Abstract][Full Text] [Related]
4. Immunological effects of adjuvanted low-dose allergoid allergen-specific immunotherapy in experimental murine house dust mite allergy.
Heldner A; Alessandrini F; Russkamp D; Heine S; Schnautz B; Chaker A; Mwange J; Carreno Velazquez TL; Heath MD; Skinner MA; Kramer MF; Zissler UM; Schmidt-Weber CB; Blank S
Allergy; 2022 Mar; 77(3):907-919. PubMed ID: 34287971
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of a microcrystalline tyrosine-adjuvanted Dermatophagoides pteronyssinus allergoid immunotherapy in adult patients with allergic asthma and rhinitis: A real-life prospective observational study.
Padró C; Gutiérrez D; Moreno F; Parra A; Rial MJ; Lleonart R; Torán-Barona C; Justicia JL; Roger A
Immun Inflamm Dis; 2022 May; 10(5):e585. PubMed ID: 35478444
[TBL] [Abstract][Full Text] [Related]
6. Real-World Safety and Effectiveness Evidence of a Microcrystalline Tyrosine-Associated Mite Allergoid in Children and Adolescents with Allergic Rhinitis.
Anna SC; Zulay M AS; Ignacio GN; Sofia L; Juan A MT; Maria D M; Ramón N; Mercedes R; Anna B; Carla TB; José L J
Allergol Immunopathol (Madr); 2021; 49(4):98-108. PubMed ID: 34224224
[TBL] [Abstract][Full Text] [Related]
7. House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study.
Jutel M; Klimek L; Richter H; Brüggenjürgen B; Vogelberg C
Allergy; 2024 Apr; 79(4):1042-1051. PubMed ID: 38429981
[TBL] [Abstract][Full Text] [Related]
8. The Functional IgE-Blocking Factor Induced by Allergen-Specific Immunotherapy Correlates with IgG4 Antibodies and a Decrease of Symptoms in House Dust Mite-Allergic Children.
Zhao D; Lai X; Tian M; Jiang Y; Zheng Y; Gjesing B; Zhong N; Spangfort MD
Int Arch Allergy Immunol; 2016; 169(2):113-20. PubMed ID: 27049773
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma.
Farraia M; Paciência I; Castro Mendes F; Cavaleiro Rufo J; H Shamji M; Agache I; Moreira A
Allergy; 2022 Sep; 77(9):2688-2698. PubMed ID: 35451128
[TBL] [Abstract][Full Text] [Related]
10. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
11. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
Richards JR; Stumpf JL
Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713
[TBL] [Abstract][Full Text] [Related]
12. Serum-specific IgE and allergen immunotherapy in allergic children.
Tosca M; Silvestri M; Accogli A; Rossi GA; Ciprandi G
Immunotherapy; 2014; 6(1):29-33. PubMed ID: 24341881
[TBL] [Abstract][Full Text] [Related]
13. Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases.
Yang Y; Ma D; Huang N; Li W; Jiang Q; Wang Y; Wang X; Yang L; Zhu R
Ital J Pediatr; 2021 Apr; 47(1):101. PubMed ID: 33892756
[TBL] [Abstract][Full Text] [Related]
14. Allergen desensitization reduces the severity of relapsed alopecia areata in dust-mite allergic patients.
Zeng Z; Li S; Ye Y; Ling Y; Gong Y; Zi X; Yang J; McElwee KJ; Zhang X
Exp Dermatol; 2023 Jul; 32(7):1108-1119. PubMed ID: 37114716
[TBL] [Abstract][Full Text] [Related]
15. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma.
Eifan AO; Calderon MA; Durham SR
Expert Opin Biol Ther; 2013 Nov; 13(11):1543-56. PubMed ID: 24099116
[TBL] [Abstract][Full Text] [Related]
16. House dust mite-specific immunotherapy alters the natural course of atopic march.
Tang RB
J Chin Med Assoc; 2020 Feb; 83(2):109-112. PubMed ID: 32015265
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of a microcrystalline tyrosine-associated mite extract immunotherapy for allergic rhinitis.
Sala-Cunill A; Pérez-Formoso JL; Torán-Barona C; Almeida-Sánchez ZM; Álvarez-Fernández JA; García-Núñez I; Linana-Santafé JJ; Martínez-Tadeo JA; Boronat-Barado A; Justicia JL
Immunotherapy; 2020 Sep; 12(13):1007-1019. PubMed ID: 32811270
[No Abstract] [Full Text] [Related]
18. A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting.
Björstad Å; Cardell LO; Hahn-Pedersen J; Svärd M
Clin Drug Investig; 2017 Jun; 37(6):541-549. PubMed ID: 28326466
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
[TBL] [Abstract][Full Text] [Related]
20. Prospective comparison of a nonmodified and a modified mite extract for immunotherapy in children and adolescents.
Hartmann D; Fischl A; Herrmann E; Schulze J; Schubert R; Zielen S
Immunotherapy; 2019 Aug; 11(12):1015-1029. PubMed ID: 31319714
[No Abstract] [Full Text] [Related]
[Next] [New Search]
